Compare Northrop Grumman Corporation (NOC) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs Tempus AI — how do they compare? Northrop Grumman Corporation trades at $484.5 (market cap $67.26B), while Tempus AI trades at $70 (market cap $12.77B). The key difference: Northrop Grumman Corporation is far larger — about 5.3× Tempus AI's market cap, and Northrop Grumman Corporation pays a 2.09% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Northrop Grumman Corporation for 81 Days and Tempus AI for 22 Days on average.
| NOC | TEM | |
|---|---|---|
Market Cap | $67.26B | $12.77B |
Volume | 711,592 | 8,980,490 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $768.02 | $99.28 |
52-Week Low | $473.46 | $41.55 |
Typical Hold Time | 81 Days | 22 Days |
Enterprise Value | $81.24B | $13.40B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Northrop Grumman (NOC) trades at $484.48, up 0.28% with a bearish technical signal despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $7.68 exceeding expectations by 12.6%. Recent news highlights the loss of a $20B Navy fighter contract to Boeing, creating near-term headwinds. Technical indicators show oversold conditions with RSI at 16.17, while the stock trades below key resistance at $484.
NOC presents a compelling value opportunity with a 15.05 P/E ratio and 26.96% ROE, supported by a 54% analyst buy rating and $615.75 price target. Risks include competitive contract losses and defense budget uncertainties, but the company's $104.7B backlog and dividend growth provide stability. The current technical weakness may offer entry points for long-term investors seeking defense exposure.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
